Press Releases

Intranasal Drug Delivery Devices Market Size is Projected to Hit Around US$ 2.98 Billion by 2030

According to Precedence Research’s new research study on “Intranasal Drug Delivery Devices Market Size 2021 to 2030 – Global Industry Analysis and Forecast (By System: Metered Dose, Multi-Dose Systems, and Unit-Dose Systems; By Container: Non-Pressurized Containers and Pressurized Containers; By Application: Chronic Obstructive Pulmonary Disease (COPD), Rhinitis, Cystic Fibrosis, Nasal Congestion, Asthma, and Others; By End User: Ambulatory Surgical Centers, Clinics, Hospitals, and Others)” The global intranasal drug delivery devices market size is forecasted to reach around US$ 2.98 billion by 2030 and is anticipated to grow with a healthy CAGR of 12.8% from 2021 to 2030.

The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1253

Drug delivery primarily refers to a process of transporting a drug/medication into the body to have an adequate therapeutic consequence. Several methods are frequently utilized for the delivery of the medicine. Nasal and pulmonary routes are regarded to be the most prevalent types for carrying the drug. Intranasal drug delivery is a convenient delivery method for medications that are active in low dosages and display no minimum oral bioavailability such as peptides and proteins. One of the explanations for the low degree of absorption of proteins and peptides via the nasal path is quick movement distant from the absorption position in the nasal cavity owing to the Mucociliary Clearance system. The nasal path evades hepatic first pass exclusion associated with the oral transfer. The rapid inception of the therapeutic outcome is possible due to the big surface area of the nasal mucosa. This method has great potential for non-invasiveness, no first-pass absorption, and direct to the central nervous system transfer.

Growth Factors:

Factors such as growing patient preference for nasal drug delivery and increasing popularity of self-administration of medications are driving the growth of intranasal drug delivery devices market. High incidence of cardiovascular disorders, increased cancer and diabetes cases, amplified focus on elderly and pediatric patients, and growing demand for home-based healthcare devices are further propelling the intranasal drug delivery devices market expansion across the globe. Additional aspects that are anticipated to fuel this industry are rapid R&D activity and reception of new drug delivery approaches and equipment’s, reformulation of injections and oral medications into the preparations to be administered by the nasal route, and quick onset of action. The simple administration and improved efficacy have amplified patient preference for the nasal drug delivery which subsequently has enhanced the demand for overall market for the nasal drug delivery devices market.

Due to the greater permeability and low enzymatic environment of the nasal cavity, and evasion of the hepatic first pass metabolism, intranasal drug delivery devices are appropriate for systemic transport of drug molecule through nose. Numerous drug delivery devices for nasal use of solid, semisolid, and liquid formulation are examined to deliver the medications to the treat most critical CNS diseases (i.e., Alzheimer’s disease, Parkinson’s disease) since it requires quick and specific aiming of medications to the brain.

Market Scope:

Report Highlights Details
Market Size US$ 2.98 Billion by 2030
Growth Rate CAGR of 12.8% from 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered CAGR of 12.8% during the forecast period 2021 to 2030.

Report Highlights:

  • Among the system segment, multi-dose systems are expected to dominate the overall market. Multi-dose systems have multiple advantages over other systems which makes them a system of choice in many settings.
  • The non-pressurized containers accounted for the largest revenue in the containers segment with more than 68% share in 2019. Increasing awareness regarding the use of non-pressurized containers is the major reason for high market share of non-pressurized containers. Pressurized containers are expected to grow at the topmost CAGR during the forecast time-frame.
  • Asthma accounted for the largest revenue in the application segment. Increasing prevalence of asthma in developing regions is the key reason for high market share of asthma.
  • Hospitals accounted for the largest revenue in the end-user segment. High frequency of intranasal drug delivery in hospitals is the key reason for high market share of hospitals.
  • Teleflex Incorporated accounted for a significant share of the global intranasal drug delivery devices market.

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2020, North America dominated the global market with a market share of more than 37%. U.S. represented the highest share in the North American region primarily due to presence of leading market players and high awareness regarding alternate drug delivery mechanisms. Furthermore, early adoption of latest healthcare technologies also contributed to the high market share of the United States.

Europe was the second important market chiefly due to presence of latest healthcare infrastructure and high investment in research and development. The presence of skilled researchers in the European region is also expected to boost the demand for Intranasal Drug Delivery Devices market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around 14% in the forecast period due to high incidence of cancer. Latin America and the African and Middle Eastern region will display noticeable growth.

Some of the prominent players in the global Intranasal Drug Delivery Devices Market are listed as below:

  • Johnson & Johnson, Inc.
  • Aptar Pharma Group
  • GlaxoSmithKline Plc
  • Aegis Therapeutics LLC
  • H&T Presspart Manufacturing Ltd.
  • AstraZeneca Plc
  • Becton, Dickinson and Company
  • Novartis AG
  • Teleflex Incorporated
  • Vectura Group Plc.

In order to better recognize the current status of intranasal drug delivery devices, and policies adopted by the foremost countries, Precedence Research predicted the future evolution of the intranasal drug delivery devices market. This research study bids qualitative and quantitative insights on intranasal drug delivery devices market and assessment of market size and growth trend for potential market segments.

Major Market Segments Covered:

By System

  • Metered Dose
  • Multi-Dose Systems
  • Unit-Dose Systems

By Container

  • Non-Pressurized Containers
  • Pressurized Containers

By Application

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion
  • Asthma
  • Others

By End User

  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1.    Introduction

1.1.    Research Objective
1.2.    Scope of the Study
1.3.    Definition

Chapter 2.    Research Methodology

2.1.    Research Approach
2.2.    Data Sources
2.3.    Assumptions& Limitations

Chapter 3.    Executive Summary

3.1.    Market Snapshot

Chapter 4.    Intranasal Drug Delivery Devices Market Variables and Scope 

4.1.    Introduction
4.2.    Market Classification and Scope

Chapter 5.    COVID 19 Impact on Intranasal Drug Delivery Devices Market

5.1.    Covid-19: Intranasal Drug Delivery Devices Industry Impact
5.2.    Intranasal Drug Delivery Devices Business Impact Assessment: Covid-19
5.2.1.    Services Challenges/Disruption
5.2.2.    Market Trends and Intranasal Drug Delivery Devices Opportunities in the COVID-19 Landscape for Major Markets
5.3.    Strategic Measures against Covid-19
5.3.1.    Government Support and Initiative to Combat Covid-19
5.3.2.    Proposal for Intranasal Drug Delivery Devices Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6.    Intranasal Drug Delivery Devices Market Dynamics Analysis and Trends

6.1.    Market Dynamics
6.1.1.    Market Drivers
6.1.1.1.    High prevalence of cardiovascular diseases
6.1.1.2.    Patent expiration of popular drugs, increased cases of cancer and diabetes
6.1.2.    Market Restraints
6.1.2.1.    Complications Associated with the Overuse
6.1.3.    Market Opportunities
6.1.3.1.    Growing adoption of self-administration practices
6.1.3.2.    Technological advancements

Chapter 7.    Global Intranasal Drug Delivery Devices Market: Competitive Landscape

7.1.1.    Company Market Share/Positioning Analysis
7.1.1.1.    Intranasal Drug Delivery Devices Market Revenue by Market Players (2016 -2019)
7.1.1.2.    Intranasal Drug Delivery Devices Market Revenue Market Share by Market Players (2016 -2019)
7.1.2.    Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1.    Product Portfolio Expansion, Geographic Expansion, System Innovation
7.1.2.2.    Merger and Acquisition, Collaboration and Partnerships
7.1.3.    Market Players Landscape
7.1.3.1.    List of Suppliers
7.1.3.2.    List of End-users

Chapter 8.    Global Intranasal Drug Delivery Devices Market, By System

8.1.    Intranasal Drug Delivery Devices Market, by System, 2016-2027
8.1.1.    Metered Dose
8.1.1.1.    Market Revenue and Forecast (2016-2027)
8.1.2.    Multi-Dose Systems
8.1.2.1.    Market Revenue and Forecast (2016-2027)
8.1.3.    Unit-Dose Systems
8.1.3.1.    Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Intranasal Drug Delivery Devices Market, By Container

9.1.    Intranasal Drug Delivery Devices Market, by Container, 2016-2027
9.1.1.    Non-Pressurized Containers
9.1.1.1.    Market Revenue and Forecast (2016-2027)
9.1.2.    Pressurized Containers
9.1.2.1.    Market Revenue and Forecast (2016-2027)

Chapter 10.    Global Intranasal Drug Delivery Devices Market, By Application

10.1.    Intranasal Drug Delivery Devices Market, by Application, 2016-2027
10.1.1.    Chronic Obstructive Pulmonary Disease (COPD)
10.1.1.1.    Market Revenue and Forecast (2016-2027)
10.1.2.    Rhinitis
10.1.2.1.    Market Revenue and Forecast (2016-2027)
10.1.3.    Cystic Fibrosis
10.1.3.1.    Market Revenue and Forecast (2016-2027)
10.1.4.    Nasal Congestion
10.1.4.1.    Market Revenue and Forecast (2016-2027)
10.1.5.    Asthma
10.1.5.1.    Market Revenue and Forecast (2016-2027)
10.1.6.    Others
10.1.6.1.    Market Revenue and Forecast (2016-2027)

Chapter 11.    Global Intranasal Drug Delivery Devices Market, By End User

11.1.    Intranasal Drug Delivery Devices Market, by End User, 2016-2027
11.1.1.    Ambulatory Surgical Centers
11.1.1.1.    Market Revenue and Forecast (2016-2027)
11.1.2.    Clinics
11.1.2.1.    Market Revenue and Forecast (2016-2027)
11.1.3.    Hospitals
11.1.3.1.    Market Revenue and Forecast (2016-2027)
11.1.4.    Others
11.1.4.1.    Market Revenue and Forecast (2016-2027)

Chapter 12.    Global Intranasal Drug Delivery DevicesMarket, Regional Estimates and Trend Forecast

12.1.    North America
12.1.1.    Market Revenue Forecast by System(2016-2027)
12.1.2.    Market Revenue Forecast by Container(2016-2027)
12.1.3.    Market Revenue Forecast by Application(2016-2027)
12.1.4.    Market Revenue Forecast by End User (2016-2027)
12.1.5.    U.S
12.1.5.1.    Market Revenue Forecast (2016-2027)
12.1.6.    Canada
12.1.6.1.    Market Revenue Forecast (2016-2027)
12.2.    Europe
12.2.1.    Market Revenue Forecast by System (2016-2027)
12.2.2.    Market Revenue Forecast by Container (2016-2027)
12.2.3.    Market Revenue Forecast by Application (2016-2027)
12.2.4.    Market Revenue Forecast by End User (2016-2027)
12.2.5.    UK
12.2.5.1.    Market Revenue Forecast (2016-2027)
12.2.6.    Germany
12.2.6.1.    Market Revenue Forecast (2016-2027)
12.2.7.    France
12.2.7.1.    Market Revenue Forecast (2016-2027)
12.2.8.    Rest of EU
12.2.8.1.    Market Revenue Forecast (2016-2027)
12.3.    Asia Pacific (APAC)
12.3.1.    Market Revenue Forecast by System (2016-2027)
12.3.2.    Market Revenue Forecast by Container (2016-2027)
12.3.3.    Market Revenue Forecast by Application (2016-2027)
12.3.4.    Market Revenue Forecast by End User (2016-2027)
12.3.5.    China
12.3.5.1.    Market Revenue Forecast (2016-2027)
12.3.6.    India
12.3.6.1.    Market Revenue Forecast (2016-2027)
12.3.7.    Japan
12.3.7.1.    Market Revenue Forecast (2016-2027)
12.3.8.    Rest of APAC
12.3.8.1.    Market Revenue Forecast (2016-2027)
12.4.    LATAM
12.4.1.    Market Revenue Forecast by System (2016-2027)
12.4.2.    Market Revenue Forecast by Container (2016-2027)
12.4.3.    Market Revenue Forecast by Application (2016-2027)
12.4.4.    Market Revenue Forecast by End User (2016-2027)
12.4.5.    Brazil
12.4.5.1.    Market Revenue Forecast (2016-2027)
12.4.6.    Rest of LATAM
12.4.6.1.    Market Revenue Forecast (2016-2027)
12.5.    Middle East and Africa (MEA)
12.5.1.    Market Revenue Forecast by System (2016-2027)
12.5.2.    Market Revenue Forecast by Container (2016-2027)
12.5.3.    Market Revenue Forecast by Application (2016-2027)
12.5.4.    Market Revenue Forecast by End User (2016-2027)
12.5.5.    GCC
12.5.5.1.    Market Revenue Forecast (2016-2027)
12.5.6.    North Africa
12.5.6.1.    Market Revenue Forecast (2016-2027)
12.5.7.    South Africa
12.5.7.1.    Market Revenue Forecast (2016-2027)
12.5.8.    Rest of MEA
12.5.8.1.    Market Revenue Forecast (2016-2027)

Chapter 13.    Company Profiles

13.1.    Johnson & Johnson, Inc.
13.1.1.    Company Overview, Business Information, Regional Presence
13.1.2.    Product Portfolio Analysis
13.1.2.1.    Product Details, Specification, Application
13.1.3.    Revenue, Price, and Gross Margin (2015-2020)
13.1.4.    Recent Developments and Strategies
13.2.    Aptar Pharma Group
13.2.1.    Company Overview, Business Information, Regional Presence
13.2.2.    Product Portfolio Analysis
13.2.2.1.    Product Details, Specification, Application
13.2.3.    Revenue, Price, and Gross Margin (2015-2020)
13.2.4.    Recent Developments and Strategies
13.3.    GlaxoSmithKline Plc
13.3.1.    Company Overview, Business Information, Regional Presence
13.3.2.    Product Portfolio Analysis
13.3.2.1.    Product Details, Specification, Application
13.3.3.    Revenue, Price, and Gross Margin (2015-2020)
13.3.4.    Recent Developments and Strategies
13.4.    Aegis Therapeutics LLC
13.4.1.    Company Overview, Business Information, Regional Presence
13.4.2.    Product Portfolio Analysis
13.4.2.1.    Product Details, Specification, Application
13.4.3.    Revenue, Price, and Gross Margin (2015-2020)
13.4.4.    Recent Developments and Strategies
13.5.    H&T Presspart Manufacturing Ltd.
13.5.1.    Company Overview, Business Information, Regional Presence
13.5.2.    Product Portfolio Analysis
13.5.2.1.    Product Details, Specification, Application
13.5.3.    Revenue, Price, and Gross Margin (2015-2020)
13.5.4.    Recent Developments and Strategies
13.6.    AstraZeneca Plc
13.6.1.    Company Overview, Business Information, Regional Presence
13.6.2.    Product Portfolio Analysis
13.6.2.1.    Product Details, Specification, Application
13.6.3.    Revenue, Price, and Gross Margin (2015-2020)
13.6.4.    Recent Developments and Strategies
13.7.    Becton, Dickinson and Company
13.7.1.    Company Overview, Business Information, Regional Presence
13.7.2.    Product Portfolio Analysis
13.7.2.1.    Product Details, Specification, Application
13.7.3.    Revenue, Price, and Gross Margin (2015-2020)
13.7.4.    Recent Developments and Strategies
13.8.    Novartis AG
13.8.1.    Company Overview, Business Information, Regional Presence
13.8.2.    Product Portfolio Analysis
13.8.2.1.    Product Details, Specification, Application
13.8.3.    Revenue, Price, and Gross Margin (2015-2020)
13.8.4.    Recent Developments and Strategies
13.9.    Teleflex Incorporated
13.9.1.    Company Overview, Business Information, Regional Presence
13.9.2.    Product Portfolio Analysis
13.9.2.1.    Product Details, Specification, Application
13.9.3.    Revenue, Price, and Gross Margin (2015-2020)
13.9.4.    Recent Developments and Strategies
13.10.    Vectura Group Plc.
13.10.1.    Company Overview, Business Information, Regional Presence
13.10.2.    Product Portfolio Analysis
13.10.2.1.    Product Details, Specification, Application
13.10.3.    Revenue, Price, and Gross Margin (2015-2020)
13.10.4.    Recent Developments and Strategies

Chapter 14.    Appendix

14.1.    About Us
14.2.    Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1253

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Show More

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Back to top button